Consensus United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
237.9 ^USD	+0.42%		+2.30%	+8.20%

Apr. 19	United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing	MT
Apr. 17	United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing	MT

Evolution of the average Target Price on United Therapeutics Corporation

Price target over the last 5 years

History of analyst recommendation changes

db40862c0d1e3266d86b58.lTuvCNMaD9fcubjvxIJw6WTjVgpuMcc9s7okf1baL-A.2FDEQ6l3bqKNgYmLja9FnAupZDhWY7dQi_BKFgGoSZrASctt4Xl7pJ3yiA~e7cc117540172da87e94e89f7008fcc3

Analyst Recommendations on United Therapeutics Corporation

United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing	Apr. 19	MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing	Apr. 17	MT
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing	Apr. 15	MT
United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing	Apr. 11	MT
United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing	Apr. 09	MT
United Therapeutics Insider Sold Shares Worth $6,957,709, According to a Recent SEC Filing	Apr. 05	MT
United Therapeutics Insider Sold Shares Worth $1,394,248, According to a Recent SEC Filing	Apr. 04	MT
United Therapeutics Insider Sold Shares Worth $7,100,981, According to a Recent SEC Filing	Mar. 25	MT
United Therapeutics Insider Sold Shares Worth $1,418,726, According to a Recent SEC Filing	Mar. 22	MT
United Therapeutics Insider Sold Shares Worth $7,088,196, According to a Recent SEC Filing	Mar. 21	MT
Goldman Sachs Upgrades United Therapeutics to Neutral From Sell, Adjusts PT to $215 From $213	Feb. 12	MT
Leerink Partners Starts United Therapeutics with Outperform Rating, $330 Price Target	Feb. 05	MT
Wedbush Lifts United Therapeutics' PT to $308 From $307 After Higher-Than-Expected Q3 Revenue Driven by Tivaso Franchise; Keeps Outperform Rating	Nov. 02	MT
Morgan Stanley Adjusts Price Target on United Therapeutics to $318 From $316, Maintains Overweight Rating	23-08-03	MT
Ladenburg Thalmann Adjusts Price Target on United Therapeutics to $268 From $256, Maintains Buy Rating	23-08-03	MT
Wedbush Lifts United Therapeutics' Price Target to $307 From $305 After 'Strong' Q2 Results, Keeps Outperform Rating	23-08-03	MT
Ladenburg Thalmann Adjusts Price Target on United Therapeutics to $256 From $285, Maintains Buy Rating	23-05-04	MT
Argus Adjusts United Therapeutics' Price Target to $280 From $300, Keeps Buy Rating	23-04-21	MT
Morgan Stanley Trims Price Target on United Therapeutics to $316 From $320, Maintains Overweight Rating	23-04-10	MT
UBS Trims Price Target on United Therapeutics to $310 From $330, Keeps Buy Rating	23-04-10	MT
Credit Suisse Lowers United Therapeutics' Price Target to $290 From $293, Maintains Outperform Rating	23-03-20	MT
UBS Adjusts United Therapeutics' Price Target to $330 From $320, Maintains Buy Rating	23-02-02	MT
Argus Adjusts Price Target on United Therapeutics to $300 From $250, Maintains Buy Rating	23-01-11	MT
UBS Initiates Coverage on United Therapeutics With Buy Rating, $320 Price Target	22-12-06	MT
Morgan Stanley Boosts Price Target on United Therapeutics to $330 From $322, Maintains Overweight Rating	22-12-06	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

237.9 USD

Average target price

285.5 USD

Spread / Average Target

+19.99%

High Price Target

375 USD

Spread / Highest target

+57.61%

Low Price Target

183 USD

Spread / Lowest Target

-23.09%

Consensus detail

Consensus revision (last 18 months)

Analysts covering United Therapeutics Corporation

Goldman Sachs
Leerink Partners
Wedbush
Morgan Stanley
Ladenburg Thalmann
Argus
UBS
Credit Suisse
Oppenheimer
HC Wainwright
JPMorgan Chase
Jefferies & Co.
BTIG
J.P. Morgan Chase

Ratings for United Therapeutics Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar